Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

TVTX - Travere Therapeutics, Inc. So'nggi... | Finranks

Home

/

TVTX

T

Travere Therapeutics, Inc. (TVTX)

NGM – Real vaqt narxi. Valyuta: USD

62.05

+1.84 (3.06%)

Bozor ochiq: Aug 12, 2026, 11:58 AM EDT

60.21

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again)

Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again)

Travere Therapeutics is downgraded from Buy to Hold after a >130% rally, reflecting competitive risks and valuation concerns. Filspari's Q2 net sales surged 96% YoY to $141M, but $3B+ peak sales guidance faces new competition in IgAN and FSGS markets. TVTX's pipeline expansion with civorebrutinib and pegtibatinase targets rare kidney and metabolic diseases, but both remain early-stage with uncertain timelines.

Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity's 46th Annual Growth Conference Presenting on Tuesday, August 11, 2026, at 3:00 p.m. ET Wells Fargo 21st Annual Healthcare Conference Tuesday, September 8, 2026 Citi 2026 Biopharma Back to School Conference Wednesday, September 9, 2026 2026 Cantor Global Healthcare Conference Presenting on Thursday, Septe.

Travere Therapeutics Q2 Earnings Call Highlights

Travere Therapeutics Q2 Earnings Call Highlights

Travere Therapeutics NASDAQ: TVTX reported second-quarter results marked by record FILSPARI demand and revenue, driven by continued growth in IgA nephropathy and an early launch in focal segmental glomerulosclerosis, or FSGS.

Travere Therapeutics, Inc. (TVTX) Q2 2026 Earnings Call Transcript

Travere Therapeutics, Inc. (TVTX) Q2 2026 Earnings Call Transcript

Travere Therapeutics, Inc. (TVTX) Q2 2026 Earnings Call Transcript

Travere (TVTX) Reports Q2 Earnings: What Key Metrics Have to Say

Travere (TVTX) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates

Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.14 per share a year ago.

Travere Therapeutics Reports Second Quarter 2026 Financial Results

Travere Therapeutics Reports Second Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its second quarter 2026 financial results and provided a corporate update. “With an exceptional second quarter, Travere has entered a new chapter of near- and long-term growth,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “Our performance reflects the strength of the company we are building and the disciplined execution of our teams as we continue to deliver on our stra.

Videolar

No Data

There is no data to display

Press-relizlar

Travere Therapeutics Reports Second Quarter 2026 Financial Results

Travere Therapeutics Reports Second Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its second quarter 2026 financial results and provided a corporate update. “With an exceptional second quarter, Travere has entered a new chapter of near- and long-term growth,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “Our performance reflects the strength of the company we are building and the disciplined execution of our teams as we continue to deliver on our stra.